Neurocrine Clinical Site

New York, New York 10128

4 studies enrolling now · 13 studies all time

What they study most

Cerebral Palsy, Congenital Adrenal Hyperplasia, Dyskinesia, Major Depressive Disorder, Schizophrenia, Tardive Dyskinesia (TD), Tourette Syndrome

Studies at this site

• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Recruiting now
• Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia — Recruiting now
• NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia — Recruiting now
• Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy — Completed
• Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia — Completed
• Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia — Stopped early
• Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) — Running, not enrolling
• Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome — Stopped early
• Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome — Completed
• Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome — Completed
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia — Completed